Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Should You Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY) gapped up prior to trading on Monday. The stock had previously closed at $11.71, but opened at $12.54. Fresenius SE & Co. shares last traded at $12.0775, with a volume of 742 shares.

Analysts Set New Price Targets

FSNUY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Fresenius SE & Co. Trading Down 0.9%

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market cap of $27.22 billion, a price-to-earnings ratio of 12.31 and a beta of 0.60. The business’s 50-day moving average price is $13.09 and its two-hundred day moving average price is $12.35.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $6.91 billion for the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. Equities analysts expect that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.